| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Liminatus Pharma, Inc.
13D/A
LIMN · 53271X108
|
14.3% |
7/14/2026
Event 7/2/2026
|
||||
| Valetudo Therapeutics LLC | 14.3% | |||||
| Chris Kim | 14.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.